Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
Source: SeekingAlpha
2026-01-30 08:51:51 ET
More on Sanofi
- Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript
- Sanofi 2025 Q4 - Results - Earnings Call Presentation
- Sanofi (SAN:CA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Sanofi anticipates profitable growth to continue over at least five years
- Sanofi Non-GAAP EPS of €1.53 beats by €0.06, revenue of €11.3B beats by €170M; issues FY26 outlook
Read the full article on Seeking Alpha
For further details see:
Sanofi graft-versus-host disease asset Rezurock gains EU approval recommendation
Banco Santander S.A. Sponsored ADR
NASDAQ: SAN
SAN Trading
-3.62% G/L:
$10.925 Last:
5,039,679 Volume:
$11.02 Open:
SAN Latest News
February 03, 2026 01:38:00 pm
Webster Financial Corporation Enters Into Merger Agreement With Banco Santander, S.A. for $12.3 Billion
SAN Stock Data
$212,542,521,684
14,572,031,202
2.7%
312
N/A
Banking
Finance
ES
Boadilla del Monte
